The in vitro antibody response of peripheral blood lymphocytes (PBL) from 19 patients with untreated systemic lupus erythematosus (SLE) was compared with that of 20 control patients and 44 normal subjects. Trinitrophenyl polyacrylamide beads (TNP-PAA) were used to induce IgM anti-TNP plaque-forming cells. SLE patients displayed a markedly depressed, and in most instances virtually absent, response. This was not due to an unusual kinetics of the response; nor could it be induced by preincubation of SLE patients' PBL. In co-cultures of SLE patients and normal PBL, the former, with few exceptions, did not exert a suppressive effect. In four patients the anti-TNP response of either unfractionated or T-depleted SLE PBL could be restored by T cells from a normal individual. Conversely in three of these patients, SLE T cells could not support the response of normal B cells, suggesting a T helper cell defect in SLE PBL. Concanavalin A (Con A)-induced suppressor cells of the antibody response could be assayed by two approaches: (a) in responder SLE patients, by the direct addition of Con A to TNP-PAA-stimulated cultures; (b) in seven patients by transfer of Con A-activated cells to the responding culture of a normal allogeneic donor. In both cases SLE PBL were able to exert a suppressive effect to the same extent as normal PBL.
INTRODUCTION
Systemic lupus erythematosus (SLE)l is characterized by several immunologic abnormalities, usually at-1Abbreviations used in this paper: AFC, antibody-forming tributed to a general lack of regulation of the immune response. The precise function of the immune system in SLE patients, however, is only partially defined. Recent studies on the ability of active SLE patients to mount an antibody response have provided conflicting results regarding defects demonstrated in vivo (1) (2) (3) or in vitro (4, 5) . The latter studies have been performed with the nonspecific stimulating agent pokeweed mitogen (PWM). We have studied the ability of SLE patients' peripheral blood lymphocytes (PBL) to mount a primary in vitro antibody response to trinitrophenyl-polyacrylamide beads (TNP-PAA). This model of specific in vitro antibody response (5) has proven to be a functional assay in normal (6) (7) (8) or pathological conditions (9, 10) . Moreover, we have been able to demonstrate a virtually abolished response to TNP-PAA in normal aged individuals (>70 yr) (8) , who respond normally to PWM (11) . This discordance stresses the importance of specific tests for a comprehensive evaluation of human B cell response.
The in vitro response to TNP-PAA requires monocytes (7) and T cells (9) . Thus, our model can be used to identify the cellular basis of a defective response. This approach allowed us to show in a previous study that allogeneic T-B mixtures can function as well as autologous mixtures, and to characterize the T cell origin of the age-related impairment of the in vitro response to TNP-PAA (8) . In addition, the response to TNP-PAA can be used as the target of Concanavalin cells; E-RFC, cells forming E rosettes with sheep erythrocytes; PBL, peripheral blood lymphomonocytic cells; A (Con A)-induced suppressor cells (9, 12) to study at least one aspect of the T-suppressor cell function.
METHODS
Subjects \ornmial conitrol popi)lationl. 44 healthy subjects from the medical and laboratory staff with an age range of 19 to 53 yr (14 females, 30 males) were studied.
Patients
39 patients who had never received either immunosuppressive drugs or corticosteroid therapy were selected for study. Administration of aspirin or nonsteroidal antiinflammatory agents was stopped at least 72 h before blood collection. These patients belonged to a control group and a SLE group.
Cotitrol patietits. 20 patients (9 females, 11 males, age range 19 to 52 vr) with osteoarthrosis, cardiac, or neurologic diseases were studied. SLE group). 19 patients fulfilling the American Rheumatism Association criteria for SLE (13) were studied. All of these patients had circulating anti-DNA antibodies as evaluated by a Farr test (14) and low serum levels of C3 and C4 complement components. There were 13 females and 6 males ranging in age from 19 to 52 yr. 15 of these patients were studied at the time of initial diagnosis of SLE and had active disease, the last 4 had moderate disease activity.
Lymphocyte cultures
Blood was heparinized with Liquemine (Roche Laboratories, Neuilly-Sur-Seine, France) and lympho-monocytic cells (PBL) were isolated on Ficoll-metrizoate. The technique for in vitro induction of a primary antibody response toward TNP-PAA has been previously reported (6) . Briefly, PBL were cultured at a 5 x 106-cells/ml concentration in culture medium containing 10% fetal bovine serum. They vere incubated either without antigen (control cultures), or with TNP-PAA beads (stimulated cultures). After 7-8 d of culture, PBL were recovered, separated from the TNP-PAA beads, and the number of anti-TNP antibody-forming cells (AFC) evaluated. Each experimental group was composed of triplicate cultures assayed separately. In some experiments, 2-mercaptoethanol (2-ME, Schwarz/Mann, Div. Becton, Dickinson & Co., Orangeburg, N. Y.) was added to the culture medium at a 50-,LM final concentration (7) . In co-culture experiments PBL from a patient and from a normal donor were cultured either separately at a 5 x 106-cells/ml concentration or together (2.5 x 106 cells of each individual/ml).
Assay for the anti-TNP response
The in vitro antibody response was assessed by enumeration of the anti-TNP AFC as already described (6) . Both TNP-sheep erythrocytes (TNP-SRBC) and SRBC were used as targets in a Jeme-type plaque assay. Indirect plaque-forming cells were assayed by using an anti-human Fc y serum diluted indicated that, as a mean, a positive allogeneic effect takes place in such co-cultures and enhances the anti-TNP response above the expected level. The mean stimulation index in co-cultures from SLE plus normal PBL did not differ from that of control patients plus normal PBL (1.76±0.49 vs. 2.13±0.56, t = 0.5424). However, it is of interest to note that PBL from four SLE patients profoundly inhibited the response of normal PBL: the mean stimulation indices of these co-cultures respectively, were 0.03, 0.04, 0.05, and 0.07 (Fig. 2) . It should be pointed out that the PBL from one of these four patients were able to respond to TNP-PAA (62 AFC/106). SLE B cells are functional. In four patients, Tdepleted and T-enriched PBL populations were prepared as described in materials and methods from PBL of two normal donors and one SLE patient. As shown in Table 1 , 5 x 106 T-depleted cells from normal donors and from the SLE patient were unable to mount an anti-TNP response upon stimulation with TNP-PAA for 7 d (two cultures assayed in duplicate for each experiment). Similarly, normal T-enriched PBL (96% E-R-FC) were unable to respond to TNP-PAA (see legend to Table I ). However, when 2.5 x 106 T-depleted normal cells were cultured with 2.5 x 106 Tenriched normal cells for 7 d in the presence of TNP-PAA, an anti-TNP response was obtained in either autologous or allogeneic mixtures. In the same way, the addition of 2.5 x 106 T-enriched PBL from the same normal donor restored an anti-TNP response from 2.5 x 106 of either unfractionated or T-depleted SLE PBL. (Fig. 4) specific in vitro B cell response of NZB x NZW mice (16) and of SLE patients (4, 5, 17, 18) is depressed. The only other study reporting results of a specific in vitro antibody response in human SLE indicated increased anti-TNP PFC (19) . In the experimental model used by Morimoto et al. (19) , no response was obtained in normal PBL cultures and the AFC response in SLE PBL cultures occurred unusually early (19, 20) , whlen no AFC were detectable in our PBL cultures of normal individuals or SLE patients. Thus, one may wonder what are the respective contributions of an in vivo preactivation and of an in vitro response in Morimoto's results.
Our in vitro findings are in agreement with those ofin vivo studies showing that SLE patients with active disease have an impaired antibody response (1-3, 21) . In rheumatoid arthritis where a polyclonal hypergammaglobulinemia is observed, we have demonstrated an impaired ability of PBL to respond to TNP-PAA (10) . In this previous study, control patients, including subjects with ankylosing spondylitis, displayed a normal in vitro response. This shows that our results in SLE and in rheumatoid arthritis patients cannot simply be explained by the presence of an inflammatory state. Several mechanisms may account for the profound impairment of the in vitro antibody response in SLE. A role for lymphocytotoxic antibodies (22, 23 ) cannot be excluded, although preincubation of SLE PBL in fetal bovine serum-containing culture medium does not improve their functional capacity. Experiments testing the effect of active SLE sera on the response of normal PBL are in progress.
Spontaneous suppressor cells have been described in murine SLE (24) and in a few patients with SLE (25) . In the present work the PBL from few SLE patients suppressed the response of normal PBL, whereas in most cases the response of such co-cultures was unchanged or enhanced. Our experimental results do not allow us to distinguish between two possible explanations for these variable results: (a) suppressor cells may be inconstant in SLE PBL; (b) all SLE PBL may contain suppressor cells but the expression of this suppressive activity toward the response of normal PBL may be restricted by histocompatibility and thus could be detected only in few patient-control pairs. Several reports have demonstrated an in vitro preactivation of SLE B cells (5, 18, 26, 27) . This point was not thoroughly examined in our study, as we did not use the reverse plaque assay. We looked for anti-TNP AFC in freshly isolated PBL of SLE patients, with negative results. This does not exclude a general in vivo B cell preactivation in SLE, but indicates that this phenomenon is unlikely to be the only explanation of the decreased response toward this specific antigen.
Because none of the mechanisms mentioned above could fully account for our results, it was important to
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investigate the cellular defect responsible for the impaired in vitro antibody response in SLE. The response of TNP-PAA requires monocytes that can apparently be replaced by 2-ME (7). The addition of2-ME does not modify the response of SLE PBL which tends to exclude a major functional defect ofmonocytes. The B cell response to TNP-PAA requires T cells (9) , and the respective T and B cell functional abilities in SLE PBL had to be tested. The B cell competence in SLE had previously been evaluated by testing whether the PWM-induced response of SLE PBL could be enhanced upon addition of either mitomycin-treated normal T cells (5) (30) . Thus, the suppressor function appears to be affected differently in SLE and aging, two conditions in which a general T cell defect is assumed to be present. Our observation in SLE is in apparent contradiction with the general idea that suppressor cell function is decreased in this disease. Such a decrease has been observed in several studies of T cell proliferative responses (23, (31) (32) (33) (34) .
In the other reported studies of human B cell response, Con A-induced suppression was found to be decreased. Fauci et al. (4) observed that SLE PBL were unable, as a mean, to suppress the PWM-induced response of normal subjects, although results varied from one patient to another. Morimoto (20) and Morimoto et al. (35) reported that Con A-activated SLE PBL were unable to suppress the normal B cell response. The same results were obtained when studying the Con A-induced suppression of PWM-driven immunoglobulin production (36, 37) . The reasons for this difference may be found in the patient population or in the in vitro model: (a) Our patients were untreated, whereas in most of the above mentioned studies, some of them received corticosteroids. Although the effect of corticosteroids on the cells involved in the regulation of B cell response is complex and far from being elucidated (38) , they may interact with suppressor cell function (39); (b) More probably the Con A-induced suppression in these models of B cell response correspond to at least partially different phenomena, according to the nature of the stimulus used. Our model of specific response may be more susceptible to suppressive signals than nonspecific activation by PWM as suggested by the following facts: lower concentrations of Con A are required to suppress (12, 40) ; and the response is still susceptible to suppression on day 2 (12) . As Con A activates more than one population of suppressor cells (41, 42 ) the response to TNP-PAA could be selectively influenced by negative signals from a subpopulation of T cells which remains unaffected in SLE. Alternatively, this response could be suppressed by a decreased (4, 43, 44) but functionally active suppressor population (44) .
In murine in vitro models of antibody response, similar discrepancies have been reported (45, 46) . Again the major difference between these studies rests on the stimulating agent used to trigger the B cell response: a defect in T-suppressor function has been evidenced with PWM (45) . These apparent contradictions underscore the complexity of the abnormal regulation of the immune response in NZB x NZW mice as well as in SLE patients. They may, in part, be explained by the recent demonstration that murine lupus is associated with a decrease in the Lyt-1+2+3+ population, rather than a disappearance of the suppressor cells themselves (47) . Awaiting a more precise definition of the T cell subsets regulating the antibody response in man, clinical studies of suppressor function should be based on the assessment of several parameters, as recently suggested by Goodwin and Williams (48) . In cultures of normal PBL the response to TNP-PAA can be differently affected by Con A-induced suppressors, by in vitro spontaneously generated suppressors (12) and by sodium periodate-induced sup-pressors (49) . Further studies of these regulatory phenomena should be useful in the interpretation of the immunological defect in SLE.
In this study we found no correlation between the disease activity and the magnitude of the in vitro antibody response. An important advantage to our study will be the sequential examination of these immune parameters in patients under treatment, taking into account the reproducibility of the in vitro response to TNP-PAA (6). Our preliminary results in rheumatoid arthritis patients show that the moderate impairment of the in vitro antibody response disappears with effective treatment (10) . In SLE patients such a study could provide a better evaluation ofthe immune status, a prerequisite for a more rational use of therapeutic agents.
